Although the second quarter did not feature any life sciences enforcement action by the FTC, there was plenty of news in and around the space. The FTC held a detailed “virtual workshop” as part of its pharmaceutical merger task force and news emerged of a potential Merck-Seagen deal that could set up an interesting test of the FTC’s new enforcement priorities. Finally, the FTC’s recent complaint seeking to stop the proposed Meta/Within transaction offers potential insight into how the new Democratic majority might approach a large pharmaceutical transaction. Antitrust + Competition lawyers Arman OrucAndrew LacySarah Jordan and Elliot Silver discuss these developments in the Antitrust + Competition Life Sciences Quarterly Update.

The post Antitrust + Competition Life Sciences Quarterly Update Q2 2022 appeared first on Life Sciences Perspectives.